受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | NNC 079202 | Storage (From the date of receipt) |
3 years -20°C powder | |
化学式 | C12H8N4O6S |
|||
分子量 | 336.28 | CAS No. | 118876-58-7 | |
Solubility (25°C)* | 体外 | DMSO | 67 mg/mL (199.23 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | NBQX (FG9202, NNC 079202) is a highly selective and competitive antagonist of AMPA receptor (AMPAR) with anti-epileptic effect. |
---|---|
in vitro | NBQX is highly selective in vitro. The IC50 value for inhibition of AMPA-evoked inward currents is 0.4 μM for NBQX. While NBQX inhibits NMDA-induced currents with IC50 value of 60 μM.[2] |
in vivo | Rats are intraperitoneally (i.p.) injected with pentylenetetrazole (PTZ, 50 mg/kg) for 28 consecutive days to establish chronic epilepsy models. Subsequently, NBQX (20 mg/kg, i.p.) is injected for 3 days for the observation of behavioral measurements of epilepsy. NBQX treatment normalizes perineuronal nets (PNNs), tenascin-R, aggrecan and neurocan levels. NBQX is sufficient to decrease seizures through increasing the latency to seizures, decrease the duration of seizure onset, and reduce the scores for the severity of seizures.[1] |
細胞アッセイ | 細胞株 | Mouse neocortical neurones |
---|---|---|
濃度 | 0.1 μM - 100 μM | |
反応時間 | -- | |
実験の流れ | Cells are continuously superfused with extracellular saline at a rate of 2.5 ml/min. After giga-seal formation the whole cell configuration is obtained by suction.The holding potential is - 60 mV and at the start of each experiment the current is measured continuously for 30 s to ensure a stable baseline. Agonist-containing solutions are delivered to the chamber through a custom-made gravity-driven flowpipe, the tip of which is placed approximately 50 μm from the cell. Application is triggered when the tubing connected to the flowpipe is compressed by a valve controlled by the Pulse software. In general, agonists are applied for 1.5 or 3 s every 45 s. The sample interval during application is 600 μs. After stable responses are obtained, the extracellular saline as well as the agonist-containing solution are replaced by solutions containing NBQX to be tested. NBQX is present until responses of a repeatable amplitude are achieved. Currents are measured at the plateau phase of the responses just before deactivation. |
|
動物実験 | 動物モデル | Male Wistar rats |
投薬量 | 20 mg/kg | |
投与方法 | IP |
|
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。